Abstract
Silymarin, a mixture of flavonolignans isolated from Silybum marianum , is known for its hepatoprotective properties. We investigated the expression of cytokines in mouse liver following treatment with 0, 10, 50, and 250 mg/kg of silymarin once daily for 5 days. A dose-related but insignificant decrease of circulating alanine aminotransferase and aspartate aminotransferase after silymarin treatment was observed, suggesting that silymarin treatment did not induce hepatic damage. Silymarin treatment caused significant increases in the expressions of transforming growth factor (TGF) β1 and c-myc in liver. No significant difference was detected among these treatments in the expression of hepatocyte growth factor, interferon γ, tumor necrosis factor α, and class II major histocompatibility complex. These results suggest that alterations of TGFβ1 and c-myc expression in the liver may be involved in the hepatoprotective effects of silymarin observed in other studies.
Key words
Silymarin - TGFβ - c-myc
- flavonoid - liver -
Silybum marianum
- Asteraceae
References
Silybum marianum ) for the therapy of liver disease.
Am J Gastroenterol.
1998;
93
149-53
Silybum marianum on kidney cells.
J Pharmacol Exp Ther.
1999;
290
1475-89
Amorpha fruticosa
.
J Ethnopharmacol.
2000;
70
137-43
Ink4b G1 arrest pathway.
Mol Cell Biol.
1999;
19
5914-22
Cip1 by c-Myc in overcoming transforming factor β-induced cell-cycle arrest.
Proc Natl Acad Sci USA.
2000;
97
9498-503
rpsharma@vet.uga.edu
